摘要
背景/目的:二肽基肽酶-4的影响(DPP-4)对血浆脂联素浓度的抑制剂,脂肪源性激素与抗动脉粥样硬化和抗炎的特性是不确定的。一项系统回顾和荟萃分析的随机对照试验(RCT)研究了在人类中的这一联系。方法:在搜索PubMed MEDLINE、SCOPUS鉴定,和谷歌学术数据库(截至二月2015)之后,随机对照试验研究DPP-4抑制剂对血浆脂联素浓度的影响被确认。作为定量数据的合成方法,应用了随机效应模型和通用的逆方差法。进行了标准方法的荟萃回归,敏感性分析和发表偏向评估。结果:进行了八个带有九个治疗组的随机对照试验。Meta分析并没有显示出显著的综合效果DPP IV抑制剂对脂联素值的影响(weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88)。然而,在维格列汀试验子集观察到血浆脂联素浓度显著升高(WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010)而不是西他列汀(WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907)。在比较DPP-4抑制剂与安慰剂或不治疗试验的子集的血浆脂联素水平显著升高(WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001)而不使用降糖药物的子集作为比较),或使用其他降糖药(WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654)。通过荟萃回归分析,在治疗时间,没有显着的影响被发现。结论:DPP-4抑制剂导致显著增加血浆脂联素浓度的影响更大,维格列汀优于西格列汀。
关键词: 脂联素,心血管疾病,二肽基肽酶抑制剂,Meta分析,系统评价,2型糖尿病。
Current Medicinal Chemistry
Title:Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Volume: 23 Issue: 13
Author(s): Amirhossein Sahebkar, Valentina Ponzo, Simona Bo
Affiliation:
关键词: 脂联素,心血管疾病,二肽基肽酶抑制剂,Meta分析,系统评价,2型糖尿病。
摘要: Background/Objectives: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on plasma concentrations of adiponectin, a fat-derived hormone with anti-atherogenic and anti-inflammatory properties, is uncertain. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate this association in humans. Methods: RCTs investigating the impact of DPP-4 inhibitors on plasma adiponectin concentrations were identified after searching PubMed-Medline, SCOPUS, and Google Scholar databases (up to February 2015). As quantitative data synthesis methods, the random-effects model and the generic inverse variance method were applied. Standard methods of meta-regression, sensitivity analysis, and publication bias assessments were performed. Results: Eight RCTs with nine treatment-arms were included. Meta-analysis did not suggest a significant pooled effect of DDP-4 inhibitors on adiponectin values (weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88). However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with vildagliptin (WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907). There was a significant elevation of plasma adiponectin levels in the subset of trials comparing DPP-4 inhibitors versus placebo or no treatment (WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001) but not in the subset using hypoglycemic drugs as comparators), or using other hypoglycemic drugs (WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654). No significant effect was found for treatment duration, confirmed by meta-regression analyses. Conclusion: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin.
Export Options
About this article
Cite this article as:
Amirhossein Sahebkar, Valentina Ponzo, Simona Bo , Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current Medicinal Chemistry 2016; 23 (13) . https://dx.doi.org/10.2174/0929867323666160405111354
DOI https://dx.doi.org/10.2174/0929867323666160405111354 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Recent Strategies Combining Biomaterials and Stem Cells for Bone, Liver and Skin Regeneration
Current Stem Cell Research & Therapy Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Phytochemical Investigation and Quantitative Analysis of the Fatty Acids and Sterol Compounds of Seven Pharmaceutical valuable Seeds
Current Pharmaceutical Analysis Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations
Current Pharmaceutical Design Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran
Cardiovascular & Hematological Disorders-Drug Targets Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Peripheral Arterial Disease and Oxidative Stress
Vascular Disease Prevention (Discontinued) Molecular Genetics of Polycystic Ovary Syndrome: An Update
Current Molecular Medicine The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews